Related references
Note: Only part of the references are listed.Evaluation of a Novel Calcium Channel Agonist for Therapeutic Potential in Lambert-Eaton Myasthenic Syndrome
Tyler B. Tarr et al.
JOURNAL OF NEUROSCIENCE (2013)
Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody
Marco Morsch et al.
JOURNAL OF PHYSIOLOGY-LONDON (2013)
The Use of Aminopyridines in Neurological Disorders
Saam Sedehizadeh et al.
CLINICAL NEUROPHARMACOLOGY (2012)
3,4-Diaminopyridine improves neuromuscular transmission in a MuSK antibody-induced mouse model of myasthenia gravis
Shuuichi Mori et al.
JOURNAL OF NEUROIMMUNOLOGY (2012)
Reversal of BoNT/A-mediated inhibition of muscle paralysis by 3,4-diaminopyridine and roscovitine in mouse phrenic nerve-hemidiaphragm preparations
Michael Adler et al.
NEUROCHEMISTRY INTERNATIONAL (2012)
Congenital Myasthenic Syndromes: Current Diagnostic and Therapeutic Approaches
Ulrike Schara et al.
NEUROPEDIATRICS (2012)
Synthesis and Biological Evaluation of a Selective N- and P/Q-Type Calcium Channel Agonist
Mary Liang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Clinical Dutch-English Lambert-Eaton Myasthenic Syndrome (LEMS) Tumor Association Prediction Score Accurately Predicts Small-Cell Lung Cancer in the LEMS
Maarten J. Titulaer et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies
Maarten J. Titulaer et al.
LANCET NEUROLOGY (2011)
Efficacy of 3,4-Diaminopyridine and Pyridostigmine in the Treatment of Lambert-Eaton Myasthenic Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study
P. W. Wirtz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
The Lambert-Eaton myasthenic syndrome 1988-2008: A clinical picture in 97 patients
M. J. Titulaer et al.
JOURNAL OF NEUROIMMUNOLOGY (2008)
(R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastorna cells to nutlin-3-induced apoptosis
Judit Ribas et al.
EXPERIMENTAL CELL RESEARCH (2006)
Slowed N-type calcium channel (CaV2.2) deactivation by the cyclin-dependent kinase inhibitor roscovitine
Z Buraei et al.
BIOPHYSICAL JOURNAL (2005)
Cell differentiation, caspase inhibition, and macromolecular synthesis blockage, but not BCL-2 or BCL-XL proteins, protect SH-SY5Y cells from apoptosis triggered by two CDK inhibitory drugs
J Ribas et al.
EXPERIMENTAL CELL RESEARCH (2004)
Passive transfer of Lambert-Eaton syndrome to mice induces dihydropyridine sensitivity of neuromuscular transmission
MT Flink et al.
JOURNAL OF PHYSIOLOGY-LONDON (2002)
Share Paper
